Different Approaches to Tech's Biggest Names

The Magnificent Seven debate continues to divide investors. Are these tech giants still the golden ticket to market-beating returns, or has the party already peaked? It's the kind of question that keeps portfolio managers up at night—and apparently, it's also occupying Congress.

While Rep. Cleo Fields (D-La.) has been making headlines for his aggressive buying of Magnificent Seven stocks worth millions of dollars in recent months, Sen. Tommy Tuberville (R-Ala.) is taking the exact opposite approach. He's been systematically trimming his exposure to tech's biggest players.

October's Exit from Tech Giants

Tuberville's latest disclosure, tracked by the MarketDash Government Trades page, shows he sold positions in three Magnificent Seven members on October 7:

• Apple Inc. (AAPL): Sold $15,000 to $50,000
• Alphabet Inc. Class A (GOOGL): Sold $15,000 to $50,000
• Microsoft Corp. (MSFT): Sold $15,000 to $50,000

But October wasn't an isolated event. Tuberville also unloaded Apple, Alphabet, and Microsoft shares in April, and sold Apple and Microsoft again in January. The pattern is clear: 2025 has been a year of selling, not buying, for the Alabama senator.

Here's the interesting part—Tuberville isn't necessarily out of these stocks entirely. According to an August 2025 filing reported by Quiver Quantitative, he owned over $100,000 in each of Apple, Alphabet, and Microsoft as of 2024. That means even after multiple rounds of selling, he likely still holds shares in all three companies. He just owns less of them now.

As for the other four members of the Magnificent Seven—Amazon, Meta, Nvidia, and Tesla—Tuberville doesn't currently own any of them.

More Than Just Tech

The October 7 selling spree extended beyond the Magnificent Seven. Tuberville also dumped positions in:

• PepsiCo (PEP): Sold $15,000 to $50,000
• Oracle Corporation (ORCL): Sold $15,000 to $50,000
• Owens Corning Inc. (OC): Sold $15,000 to $50,000

Why the selling? It could be several things. Maybe Tuberville thinks these stocks are overvalued. Maybe it's tax-loss harvesting or portfolio rebalancing. Or maybe he just needed to raise some cash. Congressional disclosure rules don't require lawmakers to explain their thinking, which leaves us reading tea leaves.

A Trading History That Raises Eyebrows

Tuberville's trading activity has attracted more than casual attention over the years. In 2024, he was actively trading options on multiple technology stocks—not just buying and holding, but making leveraged bets on companies his committees oversee.

"BREAKING: Senator Tommy Tuberville is once again trading options," Unusual Whales previously tweeted. "He is literally trading companies which he legislates on, while having leveraged positions over them. Unusual."

Then there was the Humacyte Inc. purchase that turned heads. Tuberville bought shares of the small-cap biotech, which caught attention for two reasons: its tiny market cap made it an unusual choice, and Tuberville sits on the Senate Armed Services Committee. Humacyte had previously tested its technology in Ukraine, treating combat injuries. The connection wasn't lost on observers.

The senator has been flagged multiple times for questionable trading patterns. He previously bought stock in Southern States Bancshares Inc., a regional bank whose CEO happened to be a donor to Tuberville's Senate campaign. A Business Insider report revealed he was late disclosing around 130 stock trades from January to May 2021. And the New York Times reported that Tuberville bought or sold stock and options in 17 companies that had business before Senate committees he served on.

Through it all, Tuberville has remained one of Congress's most active stock and options traders—a distinction that keeps him in the spotlight, whether he wants to be there or not.